Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects at-risk babies

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent coverage when immunised 4 weeks before birth
• Antibodies from the mother passed through placenta safeguard newborns from day one
• Protection achievable with 2-week gap before premature birth
• Vaccination in the third trimester still offers significant protection for infants

Strong evidence from the latest research

The performance of the RSV vaccine administered during pregnancy has been established through a extensive research programme carried out throughout England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across varied populations and settings.

The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction underscores the vaccine’s vital importance in protecting against serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured actual clinical results rather than laboratory-based settings, providing real-world data of how the vaccine performs when administered across diverse clinical settings and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and its risks

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to breathe and feed adequately. Parents commonly see their babies fighting for breath, their chests heaving as they attempt to draw adequate oxygen into their weakened respiratory system. Whilst the majority of babies improve through supportive care, a limited though important proportion perish from RSV complications yearly, making vaccination as prevention a essential public health imperative for defending the most vulnerable and youngest members of society.

• RSV triggers lung inflammation, leading to severe breathing difficulties in infants
• Approximately half of infants acquire the virus in their first few months of life
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• More than 20,000 UK babies require serious hospital care for RSV annually
• A small number of babies die from RSV related complications annually in the UK

Uptake rates and expert recommendations

Since the RSV vaccine programme began in 2024, health officials have emphasised the importance of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing is crucial for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.

The messaging from health authorities stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.

Regional differences in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These regional differences demonstrate variations in medical facilities, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts deploying diverse outreach initiatives to connect with women during pregnancy
• Regional disparities in vaccine uptake rates in different parts of England necessitate strategic intervention
• Regional health providers modifying schemes to align with local requirements and situations

Real-world impact and parental perspectives

The vaccine’s outstanding effectiveness provides concrete gains for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the introduction of this preventative solution, the 80% reduction in admissions represents thousands of infants shielded from serious illness. Parents no longer face the distressing scenario of watching their newborns labour to breathe or difficulty feeding, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the terrain of neonatal breathing health, offering expectant mothers a preventative option to shield their youngest infants during those vital initial period.

For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to expectant mothers during their final trimester, transforming what was once an predictable seasonal threat into a controllable health concern.